New immune cell therapy takes on childhood cancers that Won't quit

NCT ID NCT07172958

Recruiting now Disease control Sponsor: Children's National Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This early-stage trial tests a new type of cell therapy for children whose embryonal tumors (rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor) have returned or not responded to standard treatments. The therapy uses the patient's own immune cells, engineered to better recognize and attack cancer cells. The main goal is to find a safe dose and watch for serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: engineered immune cells (B7-H3 CAR T cells and PRAME-targeting T cells)
What this could lead to: If it works, this could point toward a new treatment option for children with hard-to-treat embryonal tumors that have come back or not responded to standard therapy.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not yet on effectiveness. The treatment can cause severe side effects like cytokine release syndrome and nerve toxicity. It may not shrink tumors or help patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma neuroblastoma rhabdomyosarcoma Wilms tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EWING SARCOMA NEUROBLASTOMA RHABDOMYOSARCOMA WILMS TUMOR

Contacts and locations

Locations

Children's National Hospital
RECRUITING

Washington D.C., District of Columbia, 20010, United States
Childrens National Hospital
NOT_YET_RECRUITING

Washington D.C., District of Columbia, 20010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.